Protox, a company specializing in manufacturing botulinum toxin drugs, announced on the 17th that it has signed an exclusive supply contract between Brazil and Russia for its own botulinum toxin type A (tentative name Protoxin stock).Protox is a subsidiary of KOSDAQ-listed DSK.

According to the company, through this contract, the company plans to jointly carry out phase 3 clinical trials in individual countries and obtain local product licenses for “Protoxin stocks” that have completed phase 1 and 2 clinical trials in Korea.Local partners will pay the full cost of phase 3 clinical trials in the country.

In addition, the company explained that after successful termination of phase 3 clinical trials and obtaining product licenses in the region, it will exclusively supply protoxin stocks worth 200 billion won in Brazil and 100 billion won in Russia for at least 10 years.

In Russia, applications for phase 3 clinical trials are currently underway, and local clinical trials will begin in earnest soon.Brazil also plans to carry out preliminary work for approval of phase 3 clinical trials in the region and register with the ANVISA (National Health Monitoring Agency).In addition, the company is conducting phase 3 clinical trials on 274 subjects from five domestic institutions to obtain domestic item licenses next year.

Newsis mrkt@newsis.com Reporter Kim Kyung-taek